Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Kazarian, Meleeneh ^a   Laird Offringa, Ite A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CANCER ANTIBODY; TRANSCRIPTION FACTOR SOX1; VOLTAGE GATED CALCIUM CHANNEL;

AUTOIMMUNE DISEASE; CANCER ASSOCIATED RETINOPATHY; CANCER DIAGNOSIS; CANCER SURVIVAL; CROSS REACTION; DISEASE ASSOCIATION; HUMAN; IMMUNE RESPONSE; LAMBERT EATON MYASTHENIC SYNDROME; LUNG SMALL CELL CANCER; NEUROMUSCULAR JUNCTION DISORDER; NONHUMAN; PARANEOPLASTIC ENCEPHALOMYELITIS SENSORY NEURONOPATHY; PARANEOPLASTIC SYNDROME; PROGNOSIS; RETINOPATHY; REVIEW; SENSORY NEUROPATHY; ANIMAL; AUTOIMMUNITY; DISEASE MODEL; EARLY DIAGNOSIS; IMMUNOLOGY; LUNG TUMOR; MOUSE;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; EARLY DIAGNOSIS; HUMANS; LUNG NEOPLASMS; MICE; SMALL CELL LUNG CARCINOMA;

EID: 79953119082     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-33     Document Type: Review

References (208)

1. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. 2007, Atlanta, GA: American Cancer Society.
2. 2009, Atlanta, GA: American Cancer Society.
3. Horner MJ, Ries LAG, K M, Neyman N, Aminou R, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute, Bethesda, MD. 2009, http://seer.cancer.gov/csr/1975_2006/.
4. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001, 28:3-13. 10.1016/S0093-7754(01)90072-7, 11479891.
5. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, F EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards B. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD. 2007, based on November 2006 SEER data submission, posted to the SEER web site., http://seer.cancer.gov/csr/1975_2004/.
6. Brownson RC, Chang JC, Davis JR. Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology 1992, 3:61-64. 10.1097/00001648-199201000-00012, 1313311.
7. Martinez-Garcia E, Irigoyen M, Gonzalez-Moreno O, Corrales L, Teijeira A, Salvo E, Rouzaut A. Repetitive nicotine exposure leads to a more malignant and metastasis-prone phenotype of SCLC: a molecular insight into the importance of quitting smoking during treatment. Toxicol Sci 2010, 116:467-476. 10.1093/toxsci/kfq138, 20457658.
8. Sandler AB. Chemotherapy for small cell lung cancer. Semin Oncol 2003, 30:9-25. 10.1053/sonc.2003.50012, 12635086.
9. Chin RJ, Cappellari JO, McCain TW, Case LD, Haponik EF. Increasing use of bronchoscopic needle aspiration to diagnose small cell lung cancer. Mayo Clin Proc 2000, 75:796-801. 10.4065/75.8.796, 10943232.
10. Delgado PI, Jorda M, Ganjei-Azar P. Small cell carcinoma versus other lung malignancies: diagnosis by fine-needle aspiration cytology. Cancer 2000, 90:279-285. 10.1002/1097-0142(20001025)90:5<279::AID-CNCR3>3.0.CO;2-D, 11038424.
11. Tondini M, Rizzi A. Small-cell lung cancer: importance of fiberoptic bronchoscopy in the evaluation of complete remission. Tumori 1989, 75:266-268.
12. Annema JT, Versteegh MI, Veselic M, Voigt P, Rabe KF. Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of lung cancer and its impact on surgical staging. J Clin Oncol 2005, 23:8357-8361. 10.1200/JCO.2005.01.1965, 16219935.
13. Travis WD, Colby TV, Corrin B. Histological Typing of Lung Cancer and Pleural Tumors. WHO International Histological Classification of Tumors 1999, 29. Berlin: Springer, 3.
14. DeMay RM. Soft tissue tumors 1996, Chicago, IL: ASCO Press, 1.
15. Cristallini EG, Ascani S, Farabi R, Paganelli C, Peciarolo A, Bolis GB. Fine needle aspiration biopsy in the diagnosis of intrathoracic masses. Acta Cytol 1992, 36:416-422.
16. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005, 366:1385-1396. 10.1016/S0140-6736(05)67569-1, 16226617.
17. Schiller JH, Jones JC. Paraneoplastic syndromes associated with lung cancer. Curr Opin Oncol 1993, 5:335-342. 10.1097/00001622-199303000-00012, 8457618.
18. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003, 349:1543-1554. 10.1056/NEJMra023009, 14561798.
19. Voltz RD, Posner JB, Dalmau J, Graus F. Paraneoplastic encephalomyelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumour. J Neurol Neurosurg Psychiatry 1997, 63:133-136. 10.1136/jnnp.63.2.133, 2169668, 9285445.
20. Lang B, Vincent A. Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Curr Opin Immunol 1996, 8:865-871. 10.1016/S0952-7915(96)80017-3, 8994868.
21. Posner JB, Dalmau J. Paraneoplastic syndromes. Curr Opin Immunol 1997, 9:723-729. 10.1016/S0952-7915(97)80055-6, 9368783.
22. Musunuru K, Darnell RB. Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration. Annu Rev Neurosci 2001, 24:239-262. 10.1146/annurev.neuro.24.1.239, 11283311.
23. Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology 1985, 35:538-543.
24. Graus F, Elkon KB, Cordon-Cardo C, Posner JB. Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med 1986, 80:45-52. 10.1016/0002-9343(86)90047-1, 2417479.
25. Graus F, Elkon KB, Lloberes P, Ribalta T, Torres A, Ussetti P, Valls J, Obach J, Agusti-Vidal A. Neuronal antinuclear antibody (anti-Hu) in paraneoplastic encephalomyelitis simulating acute polyneuritis. Acta Neurol Scand 1987, 75:249-252. 10.1111/j.1600-0404.1987.tb07928.x, 3035860.
26. Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Ann NeurolAnn Neurol 1990, 27:544-552.
27. Saiz A, Dalmau J, Butler MH, Chen Q, Delattre JY, De Camilli P, Graus F. Anti-amphiphysin I antibodies in patients with paraneoplastic neurological disorders associated with small cell lung carcinoma. J Neurol Neurosurg Psychiatry 1999, 66:214-217. 10.1136/jnnp.66.2.214, 1736210, 10071102.
28. Knudsen A, Monstad SE, Dorum A, Lonning PE, Salvesen HB, Drivsholm L, Aarseth JH, Vedeler CA. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunol Immunother 2006, 55:1280-1284. 10.1007/s00262-006-0121-2, 16429314.
29. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004, 56:715-719. 10.1002/ana.20269, 15468074.
30. Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008, 70:924-928. 10.1212/01.wnl.0000281663.81079.24, 18032743.
31. Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, Thijssen PE, Wirtz PW, Twijnstra A, Smitt PA, van der Maarel SM, Verschuuren JJ. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009, 27:4260-4267. 10.1200/JCO.2008.20.6169, 19667272.
32. Ducray F, Graus F, Vigliani MC, Antoine JC, Rogemond V, Saiz A, Honnorat J. Delayed onset of a second paraneoplastic neurological syndrome in eight patients. J Neurol Neurosurg Psychiatry 2010, 81:937-939. 10.1136/jnnp.2009.190199, 20562403.
33. Vincent A, Honnorat J, Antoine JC, Giometto B, Dalmau J, Lang B. Autoimmunity in paraneoplastic neurological disorders. J Neuroimmunol 1998, 84:105-109. 10.1016/S0165-5728(97)00212-9, 9600714.
34. Sutton I, Winer JB. The immunopathogenesis of paraneoplastic neurological syndromes. Clin Sci (Lond) 2002, 102:475-486. 10.1042/CS20010121, 11980564.
35. Wilkinson PC, Zeromski J. Immunofluorescent detection of antibodies against neurones in sensory carcinomatous neuropathy. Brain 1965, 88:529-583. 10.1093/brain/88.3.529, 5318822.
36. Szabo A, Dalmau J, Manley G, Rosenfeld M, Wong E, Henson J, Posner JB, Furneaux HM. HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell 1991, 67:325-333. 10.1016/0092-8674(91)90184-Z, 1655278.
37. Good PJ. A conserved family of elav-like genes in vertebrates. Proc Natl Acad Sci USA 1995, 92:4557-4561. 10.1073/pnas.92.10.4557, 41983, 7753842.
38. Okano HJ, Darnell RB. A hierarchy of Hu RNA binding proteins in developing and adult neurons. J Neurosci 1997, 17:3024-3037.
39. Ball NS, King PH. Neuron-specific hel-N1 and HuD as novel molecular markers of neuroblastoma: a correlation of HuD messenger RNA levels with favorable prognostic features. Clin Cancer Res 1997, 3:1859-1865.
40. Akamatsu W, Okano HJ, Osumi N, Inoue T, Nakamura S, Sakakibara S, Miura M, Matsuo N, Darnell RB, Okano H. Mammalian ELAV-like neuronal RNA-binding proteins HuB and HuC promote neuronal development in both the central and the peripheral nervous systems. Proc Natl Acad Sci USA 1999, 96:9885-9890. 10.1073/pnas.96.17.9885, 22305, 10449789.
41. Dalmau J, Graus F, Cheung N, Rosenblum MK, Ho A, Canete A, Delattre JY, Thompson SJ, Posner JB. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer 1995, 75:99-109. 10.1002/1097-0142(19950101)75:1<99::AID-CNCR2820750117>3.0.CO;2-I, 7804984.
42. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992, 71:59-72.
43. Dalmau J, Furneaux HM, Rosenblum MK, Graus F, Posner JB. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/sensory neuronopathy. Neurology 1991, 41:1757-1764.
44. King PH, Redden D, Palmgren JS, Nabors LB, Lennon VA. Hu antigen specificities of ANNA-I autoantibodies in paraneoplastic neurological disease. J Autoimmun 1999, 13:435-443. 10.1006/jaut.1999.0337, 10585760.
45. Manley GT, Smitt PS, Dalmau J, Posner JB. Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol 1995, 38:102-110. 10.1002/ana.410380117, 7541976.
46. Sillevis Smit P, Manley G, Dalmau J, Posner J. The HuD paraneoplastic protein shares immunogenic regions between PEM/PSN patients and several strains and species of experimental animals. J Neuroimmunol 1996, 71:199-206. 10.1016/S0165-5728(96)00153-1, 8982120.
47. Sodeyama N, Ishida K, Jaeckle KA, Zhang L, Azuma A, Yamada M, Mizusawa H, Wada Y. Pattern of epitopic reactivity of the anti-Hu antibody on HuD with and without paraneoplastic syndrome. J Neurol Neurosurg Psychiatry 1999, 66:97-99. 10.1136/jnnp.66.1.97, 1736149, 9886463.
48. Kazarian M, Calbo J, Proost N, Carpenter CL, Berns A, Laird-Offringa IA. Immune response in lung cancer mouse model mimics human anti-Hu reactivity. J Neuroimmunol 2009, 217:38-45. 10.1016/j.jneuroim.2009.08.014, 2788043, 19765830.
49. Dalmau JO, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 1997, 24:318-328.
50. Monstad SE, Drivsholm L, Storstein A, Aarseth JH, Haugen M, Lang B, Vincent A, Vedeler CA. Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol 2004, 22:795-800. 10.1200/JCO.2004.01.028, 14990634.
51. Verschuuren JJ, Perquin M, ten Velde G, De Baets M, Vriesman PB, Twijnstra A. Anti-Hu antibody titre and brain metastases before and after treatment for small cell lung cancer. J Neurol Neurosurg Psychiatry 1999, 67:353-357. 10.1136/jnnp.67.3.353, 1736513, 10449558.
52. Tsou JA, Kazarian M, Patel A, Galler JS, Laird-Offringa IA, Carpenter CL, London SJ. Low level anti-Hu reactivity: A risk marker for small cell lung cancer?. Cancer Detect Prev 2009, 32:292-299. 10.1016/j.cdp.2008.06.006, 2952929, 19070439.
53. Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 1956, 187:612-613.
54. O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988, 111:577-596.
55. Ramos-Yeo YL, Reyes CV. Myasthenic syndrome (Eaton-Lambert syndrome) associated with pulmonary adenocarcinoma. J Surg Oncol 1987, 34:239-242. 10.1002/jso.2930340405, 3031377.
56. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler C, Verschuuren JJ, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004, 75:1135-1140. 10.1136/jnnp.2003.034447, 1739186, 15258215.
57. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008, 26:4276-4281. 10.1200/JCO.2008.17.5133, 18779614.
58. McCann FV, Pettengill OS, Cole JJ, Russell JA, Sorenson GD. Calcium spike electrogenesis and other electrical activity in continuously cultured small cell carcinoma of the lung. Science 1981, 212:1155-1157. 10.1126/science.6262914, 6262914.
59. Randall A, Tsien RW. Pharmacological dissection of multiple types of Ca2+ channel currents in rat cerebellar granule neurons. J Neurosci 1995, 15:2995-3012.
60. Llinas R, Sugimori M, Hillman DE, Cherksey B. Distribution and functional significance of the P-type, voltage-dependent Ca2+ channels in the mammalian central nervous system. Trends Neurosci 1992, 15:351-355. 10.1016/0166-2236(92)90053-B, 1382335.
61. Mintz IM, Adams ME, Bean BP. P-type calcium channels in rat central and peripheral neurons. Neuron 1992, 9:85-95. 10.1016/0896-6273(92)90223-Z, 1321648.
62. Iwasa K, Takamori M, Komai K, Mori Y. Recombinant calcium channel is recognized by Lambert-Eaton myasthenic syndrome antibodies. Neurology 2000, 54:757-759.
63. Takamori M, Iwasa K, Komai K. Antibodies to synthetic peptides of the alpha1A subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Neurology 1997, 48:1261-1265.
64. Parsons KT, Kwok WW. Linear B-cell epitopes in Lambert-Eaton myasthenic syndrome defined by cell-free synthetic peptide binding. J Neuroimmunol 2002, 126:190-195. 10.1016/S0165-5728(02)00063-2, 12020970.
65. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990, 40:1552-1556.
66. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997, 147:35-42. 10.1016/S0022-510X(96)05303-8, 9094058.
67. Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 1985, 317:737-739. 10.1038/317737a0, 2414666.
68. De Aizpurua HJ, Griesmann GE, Lambert EH, Lennon VA. Voltage-dependent Ca2+ channels in small cell carcinomas are blocked by autoantibodies from patients with Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 1988, 540:369-371. 10.1111/j.1749-6632.1988.tb27102.x, 2849894.
69. De Aizpurua HJ, Lambert EH, Griesmann GE, Olivera BM, Lennon VA. Antagonism of voltage-gated calcium channels in small cell carcinomas of patients with and without Lambert-Eaton myasthenic syndrome by autoantibodies omega-conotoxin and adenosine. Cancer Res 1988, 48:4719-4724.
70. Lang B, Newsom-Davis J, Prior C, Wray D. Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse. J Physiol 1983, 344:335-345. 1193844, 6655585.
71. Kim YI. Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve 1986, 9:523-530. 10.1002/mus.880090608, 3016532.
72. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci USA 1983, 80:7636-7640. 10.1073/pnas.80.24.7636, 534395, 6584877.
73. Meriney SD, Hulsizer SC, Lennon VA, Grinnell AD. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol 1996, 40:739-749. 10.1002/ana.410400510, 8957015.
74. Oguro-Okano M, Griesmann GE, Wieben ED, Slaymaker SJ, Snutch TP, Lennon VA. Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clin Proc 1992, 67:1150-1159.
75. Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci 2008, 1132:129-134. 10.1196/annals.1405.030, 18567862.
76. Titulaer MJ, Wirtz PW, Kuks JB, Schelhaas HJ, van der Kooi AJ, Faber CG, van der Pol WL, de Visser M, Sillevis Smitt PA, Verschuuren JJ. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol 2008, 201-202:153-158. 10.1016/j.jneuroim.2008.05.025, 18644631.
77. Pellkofer HL, Armbruster L, Krumbholz M, Titulaer MJ, Verschuuren JJ, Schumm F, Voltz R. Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel. J Neuroimmunol 2008, 204:136-139. 10.1016/j.jneuroim.2008.08.002, 18809213.
78. Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, Dalmau J. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 2005, 165:166-171. 10.1016/j.jneuroim.2005.03.020, 2586939, 15949849.
79. Yamada K, Watanabe M. Cytodifferentiation of Bergmann glia and its relationship with Purkinje cells. Anat Sci Int 2002, 77:94-108. 10.1046/j.0022-7722.2002.00021.x, 12418089.
80. Gure AO, Stockert E, Scanlan MJ, Keresztes RS, Jager D, Altorki NK, Old LJ, Chen YT. Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci USA 2000, 97:4198-4203. 10.1073/pnas.97.8.4198, 18195, 10760287.
81. Pevny L, Placzek M. SOX genes and neural progenitor identity. Curr Opin Neurobiol 2005, 15:7-13. 10.1016/j.conb.2005.01.016, 15721738.
82. Thirkill CE, Roth AM, Keltner JL. Cancer-associated retinopathy. Arch Ophthalmol 1987, 105:372-375.
83. Polans AS, Buczylko J, Crabb J, Palczewski K. A photoreceptor calcium binding protein is recognized by autoantibodies obtained from patients with cancer-associated retinopathy. J Cell Biol 1991, 112:981-989. 10.1083/jcb.112.5.981, 2288874, 1999465.
84. Thirkill CE, Tait RC, Tyler NK, Roth AM, Keltner JL. The cancer-associated retinopathy antigen is a recoverin-like protein. Invest Ophthalmol Vis Sci 1992, 33:2768-2772.
85. Dizhoor AM, Ray S, Kumar S, Niemi G, Spencer M, Brolley D, Walsh KA, Philipov PP, Hurley JB, Stryer L. Recoverin: a calcium sensitive activator of retinal rod guanylate cyclase. Science 1991, 251:915-918. 10.1126/science.1672047, 1672047.
86. Keltner JL, Roth AM, Chang RS. Photoreceptor degeneration. Possible autoimmune disorder. Arch Ophthalmol 1983, 101:564-569.
87. Bazhin AV, Savchenko MS, Shifrina ON, Demoura SA, Chikina SY, Jaques G, Kogan EA, Chuchalin AG, Philippov PP. Recoverin as a paraneoplastic antigen in lung cancer: the occurrence of anti-recoverin autoantibodies in sera and recoverin in tumors. Lung Cancer 2004, 44:193-198. 10.1016/j.lungcan.2003.10.006, 15084384.
88. Graus F, Dalmou J, Rene R, Tora M, Malats N, Verschuuren JJ, Cardenal F, Vinolas N, Garcia del Muro J, Vadell C, Mason WP, Rosell R, Posner JB, Real FX. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997, 15:2866-2872.
89. Dalmau J, Furneaux HM, Cordon-Cardo C, Posner J. The expression of the Hu(paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Path 1992, 141:881-886. 1886624, 1415481.
90. DeLuca I, Blachere NE, Santomasso B, Darnell RB. Tolerance to the neuron-specific paraneoplastic HuD antigen. PLoS ONE 2009, 4:e5739. 10.1371/journal.pone.0005739, 2688029, 19492067.
91. Wucherpfennig KW. Autoimmunity in the central nervous system: mechanisms of antigen presentation and recognition. Clin Immunol Immunopathol 1994, 72:293-306. 10.1006/clin.1994.1145, 8062444.
92. D'Alessandro V, Muscarella LA, la Torre A, Bisceglia M, Parrella P, Scaramuzzi G, Storlazzi CT, Trombetta D, Kok K, De Cata A, Sperandeo M, Zelante L, Carella M, Vendemiale G. Molecular analysis of the HuD gene in neuroendocrine lung cancers. Lung Cancer 2010, 67:69-75.
93. Sekido Y, Bader SA, Carbone DP, Johnson BE, Minna JD. Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines. Cancer Res 1994, 54:4988-4992.
94. Carpentier AF, Voltz R, DesChamps T, Posner JB, Dalmau J, Rosenfeld MR. Absence of HuD gene mutations in paraneoplastic small cell lung cancer tissue. Neurology 1998, 50:1919.
95. Corradi JP, Yang C, Darnell JC, Dalmau J, Darnell RB. A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. J Neurosci 1997, 17:1406-1415.
96. Uy R, Wold F. Posttranslational covalent modification of proteins. Science 1977, 198:890-896. 10.1126/science.337487, 337487.
97. Doyle HA, Mamula MJ. Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol 2001, 22:443-449. 10.1016/S1471-4906(01)01976-7, 11473834.
98. Anderton SM. Post-translational modifications of self antigens: implications for autoimmunity. Curr Opin Immunol 2004, 16:753-758. 10.1016/j.coi.2004.09.001, 15511669.
99. Zamvil SS, Mitchell DJ, Moore AC, Kitamura K, Steinman L, Rothbard JB. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 1986, 324:258-260. 10.1038/324258a0, 2431317.
100. Doyle HA, Gee RJ, Mamula MJ. Altered immunogenicity of isoaspartate containing proteins. Autoimmunity 2007, 40:131-137. 10.1080/08916930601165180, 17453712.
101. Selman MH, Niks EH, Titulaer MJ, Verschuuren JJ, Wuhrer M, Deelder AM. IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. J Proteome Res 2011, 10:143-152. 10.1021/pr1004373, 20672848.
102. Bach JF, Koutouzov S, van Endert PM. Are there unique autoantigens triggering autoimmune diseases?. Immunol Rev 1998, 164:139-155. 10.1111/j.1600-065X.1998.tb01216.x, 9795772.
103. Black J, Nelson TR, Snow K, Lennon VA. Immunogenicity of P/Q-type calcium channel in small cell lung cancer: investigation of alpha1 subunit polyglutamine expansion. Tissue Antigens 1999, 54:592-596. 10.1034/j.1399-0039.1999.540609.x, 10674974.
104. Tschernatsch M, Klotz M, Probst C, Hosch J, Valtorta F, Diener M, Gerriets T, Kaps M, Schafer KH, Blaes F. Synaptophysin is an autoantigen in paraneoplastic neuropathy. J Neuroimmunol 2008, 197:81-86. 10.1016/j.jneuroim.2008.03.018, 18479754.
105. Buckanovich RJ, Yang YY, Darnell RB. The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci 1996, 16:1114-1122.
106. Ohguro H, Nakazawa M. Pathological roles of recoverin in cancer-associated retinopathy. Adv Exp Med Biol 2002, 514:109-124.
107. Maeda T, Maeda A, Maruyama I, Ogawa KI, Kuroki Y, Sahara H, Sato N, Ohguro H. Mechanisms of photoreceptor cell death in cancer-associated retinopathy. Invest Ophthalmol Vis Sci 2001, 42:705-712.
108. Adamus G, Guy J, Schmied JL, Arendt A, Hargrave PA. Role of anti-recoverin autoantibodies in cancer-associated retinopathy. Invest Ophthalmol Vis Sci 1993, 34:2626-2633.
109. Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity and the brain. Proc Natl Acad Sci USA 1996, 93:4529-4536. 10.1073/pnas.93.10.4529, 39311, 8643438.
110. Carpentier AF, Rosenfeld MR, Delattre JY, Whalen RG, Posner JB, Dalmau J. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res 1998, 4:2819-2824.
111. Sillevis SP, Manley GT, Posner JB. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology 1995, 45:1873-1878.
112. Voltz R, Dalmau J, Posner JB, Rosenfeld MR. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology 1998, 51:1146-1150.
113. Tanaka M, Maruyama Y, Sugie M, Motizuki H, Kamakura K, Tanaka K. Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome. J Neurol Sci 2002, 201:9-12. 10.1016/S0022-510X(02)00157-0, 12163187.
114. Roberts WK, Deluca IJ, Thomas A, Fak J, Williams T, Buckley N, Dousmanis AG, Posner JB, Darnell RB. Patients with lung cancer and paraneoplastic Hu syndrome harbor HuD-specific type 2 CD8+ T cells. J Clin Invest 2009, 119:2042-2051. 2701858, 19509467.
115. Rousseau A, Benyahia B, Dalmau J, Connan F, Guillet JG, Delattre JY, Choppin J. T cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol 2005, 71:231-236. 10.1007/s11060-004-1723-1, 2586925, 15735910.
116. de Beukelaar JW, Milikan JC, Verjans GM, de Graaf MT, van Norden Y, Lamers CH, van den Bent MJ, Bromberg JE, Hulsenboom E, Sintnicolaas K, Gratama JW, Sillevis Smitt PA. No evidence for the presence of HuD-specific T cells in the cerebrospinal fluid of patients with Hu-associated paraneoplastic neurological syndromes. J Neurol 2009, 256:279-282. 10.1007/s00415-009-0051-y, 19252764.
117. de Beukelaar JW, Verjans GM, van Norden Y, Milikan JC, Kraan J, Hooijkaas H, Sintnicolaas K, Gratama JW, Sillevis Smitt PA. No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies. Cancer Immunol Immunother 2007, 56:1501-1506. 10.1007/s00262-007-0295-2, 1914259, 17597332.
118. Corriveau RA, Huh GS, Shatz CJ. Regulation of class I MHC gene expression in the developing and mature CNS by neural activity. Neuron 1998, 21:505-520. 10.1016/S0896-6273(00)80562-0, 9768838.
119. Wing K, Fehervari Z, Sakaguchi S. Emerging possibilities in the development and function of regulatory T cells. Int Immunol 2006, 18:991-1000. 10.1093/intimm/dxl044, 16720616.
120. Sansom DM, Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev 2006, 212:131-148. 10.1111/j.0105-2896.2006.00419.x, 16903911.
121. Tani T, Tanaka K, Idezuka J, Nishizawa M. Regulatory T cells in paraneoplastic neurological syndromes. J Neuroimmunol 2008, 196:166-169. 10.1016/j.jneuroim.2008.03.002, 18455243.
122. Tanaka K, Tanaka M, Onodera O, Igarashi S, Miyatake T, Tsuji S. Passive transfer and active immunization with the recombinant leucine-zipper (Yo) protein as an attempt to establish an animal model of paraneoplastic cerebellar degeneration. J Neurol Sci 1994, 127:153-158. 10.1016/0022-510X(94)90067-1, 7707074.
123. Tanaka K, Tanaka M, Igarashi S, Onodera O, Miyatake T, Tsuji S. Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of murine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar degeneration lymphocytes in severe combined immunodeficiency mice. Clin Neurol Neurosurg 1995, 97:101-105. 10.1016/0303-8467(95)00006-6, 7788964.
124. Pellkofer H, Schubart AS, Hoftberger R, Schutze N, Pagany M, Schuller M, Lassmann H, Hohlfeld R, Voltz R, Linington C. Modelling paraneoplastic CNS disease: T-cells specific for the onconeuronal antigen PNMA1 mediate autoimmune encephalomyelitis in the rat. Brain 2004, 127:1822-1830. 10.1093/brain/awh205, 15201193.
125. Lu Y, He S, Jia L, Khan NW, Heckenlively JR. Two mouse models for recoverin-associated autoimmune retinopathy. Mol Vis 2010, 16:1936-1948. 2957304, 21031137.
126. Geis C, Weishaupt A, Hallermann S, Grunewald B, Wessig C, Wultsch T, Reif A, Byts N, Beck M, Jablonka S, Boettger MK, Uceyler N, Fouquet W, Gerlach M, Meinck HM, Siren AL, Sigrist SJ, Toyka KV, Heckmann M, Sommer C. Stiff person syndrome-associated autoantibodies to amphiphysin mediate reduced GABAergic inhibition. Brain 2010, 133:3166-3180. 10.1093/brain/awq253, 20884644.
127. Linnoila RI, Zhao B, DeMayo JL, Nelkin BD, Baylin SB, DeMayo FJ, Ball DW. Constitutive achaete-scute homologue-1 promotes airway dysplasia and lung neuroendocrine tumors in transgenic mice. Cancer Res 2000, 60:4005-4009.
128. Kuo TH, Kubota T, Watanabe M, Furukawa T, Kase S, Tanino H, Nishibori H, Saikawa Y, Teramoto T, Ihsibiki K. Orthotopic reconstitution of human small-cell lung carcinoma after intravenous transplantation in SCID mice. Anticancer Res 1992, 12:1407-1410.
129. Hann CL, Daniel VC, Sugar EA, Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL, Watkins DN, Rudin CM. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 2008, 68:2321-2328. 10.1158/0008-5472.CAN-07-5031, 18381439.
130. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, Yung R, Parmigiani G, Dorsch M, Peacock CD, Watkins DN. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009, 69:3364-3373. 10.1158/0008-5472.CAN-08-4210, 2821899, 19351829.
131. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003, 4:181-189. 10.1016/S1535-6108(03)00220-4, 14522252.
132. Calbo J, Meuwissen R, van Montfort E, van Tellingen O, Berns A. Genotype-phenotype relationships in a mouse model for human small-cell lung cancer. Cold Spring Harb Symp Quant Biol 2005, 70:225-232. 10.1101/sqb.2005.70.026, 16869758.
133. Gouyer V, Gazzeri S, Brambilla E, Bolon I, Moro D, Perron P, Benabid AL, Brambilla C. Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrine lung carcinomas. Int J Cancer 1994, 58:818-824. 10.1002/ijc.2910580612, 7927874.
134. Claudio PP, Tonini T, Giordano A. The retinoblastoma family: twins or distant cousins?. Genome Biol 2002, 3:reviews3012. 10.1186/gb-2002-3-9-reviews3012, 139411, 12225593.
135. Helin K, Holm K, Niebuhr A, Eiberg H, Tommerup N, Hougaard S, Poulsen HS, Spang-Thomsen M, Norgaard P. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci USA 1997, 94:6933-6938. 10.1073/pnas.94.13.6933, 21262, 9192669.
136. Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, Karnezis AN, Sweet-Cordero EA, Sage J. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res 2010, 70:3877-3883. 10.1158/0008-5472.CAN-09-4228, 20406986.
137. Maddison P, Lang B. Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer. J Neuroimmunol 2008, 201-202:159-162. 10.1016/j.jneuroim.2008.05.024, 18667241.
138. Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993, 341:21-22. 10.1016/0140-6736(93)92485-C, 8093269.
139. Maddison P, Newsom-Davis J, Mills KR, Souhami RL. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 1999, 353(9147):117-118. 10.1016/S0140-6736(05)76153-5, 10023900.
140. Graus F, Dalmau J. Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol 2007, 20:732-737.
141. Sillevis Smitt P, Grefkens J, de Leeuw B, van den Bent M, van Putten W, Hooijkaas H, Vecht C. Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 2002, 249:745-753. 10.1007/s00415-002-0706-4, 12111309.
142. Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, Chapuis F, Aguera M, Decullier E, Duchemin AM, Graus F, Antoine JC. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009, 80:412-416. 10.1136/jnnp.2007.138016, 2664637, 18931014.
143. Aguirre-Cruz L, Charuel JL, Carpentier AF, Benyahia B, Delattre JY, Musset L. Clinical relevance of non-neuronal auto-antibodies in patients with anti-Hu or anti-Yo paraneoplastic diseases. J Neurooncol 2005, 71:39-41. 10.1007/s11060-004-4536-3, 15719273.
144. Payne M, Bradbury P, Lang B, Vincent A, Han C, Newsom-Davis J, Talbot D. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer. J Thorac Oncol 2010, 5:34-38. 10.1097/JTO.0b013e3181c3f4f1, 19934775.
145. Sullivan Pepe M, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93:1054-1061. 10.1093/jnci/93.14.1054, 11459866.
146. Warner E, Jotkowitz A, Maimon N. Lung cancer screening--are we there yet?. Eur J Intern Med 2010, 21:6-11. 10.1016/j.ejim.2009.10.004, 20122605.
147. Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanche JP, Confavreux C, Vighetto A, Renault-Mannel V, Michel D, Honnorat J. [18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol 2000, 48:105-108. 10.1002/1531-8249(200007)48:1<105::AID-ANA16>3.0.CO;2-G, 10894223.
148. Henschke CI, Yankelevitz DF, Naidich DP, McCauley DI, McGuinness G, Libby DM, Smith JP, Pasmantier MW, Miettinen OS. CT screening for lung cancer: suspiciousness of nodules according to size on baseline scans. Radiology 2004, 231:164-168. 10.1148/radiol.2311030634, 14990809.
149. Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby DM, Pasmantier MW, Koizumi J, Altorki NK, Smith JP. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999, 354:99-105. 10.1016/S0140-6736(99)06093-6, 10408484.
150. Henschke CI, Naidich DP, Yankelevitz DF, McGuinness G, McCauley DI, Smith JP, Libby D, Pasmantier M, Vazquez M, Koizumi J, Flieder D, Altorki N, Miettinen OS. Early lung cancer action project: initial findings on repeat screenings. Cancer 2001, 92:153-159. 10.1002/1097-0142(20010701)92:1<153::AID-CNCR1303>3.0.CO;2-S, 11443621.
151. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006, 355:1763-1771. 10.1056/NEJMoa060476, 17065637.
152. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA 2007, 297:953-961. 10.1001/jama.297.9.953, 17341709.
153. Jett JR. Limitations of screening for lung cancer with low-dose spiral computed tomography. Clin Cancer Res 2005, 11:4988s-4992s. 10.1158/1078-0432.CCR-05-9000, 16000601.
154. Swensen SJ, Jett JR, Sloan JA, Midthun DE, Hartman TE, Sykes AM, Aughenbaugh GL, Zink FE, Hillman SL, Noetzel GR, Marks RS, Clayton AC, Pairolero PC. Screening for lung cancer with low-dose spiral computed tomography. Am J Respir Crit Care Med 2002, 165:508-513.
155. Anglim PP, Alonzo TT, Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer 2008, 7:81. 10.1186/1476-4598-7-81, 2585582, 18947422.
156. Bach PB, Silvestri GA, Hanger M, Jett JR. Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:69S-77S. 10.1378/chest.07-1349, 17873161.
157. Aberle DR, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, Gohagan JK, Hillman B, Jaffe C, Kramer BS, Lynch D, Marcus PM, Schnall M, Sullivan DC, Sullivan D, Zylak CJ. The National Lung Screening Trial: overview and study design. Radiology 2011, 258:243-253. 10.1148/radiol.10091808, 21045183.
158. Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005, 4:1123-1133. 10.1021/pr0500814, 2522321, 16083262.
159. Averbeck M, Gebhardt C, Emmrich F, Treudler R, Simon JC. Immunologic principles of allergic disease. J Dtsch Dermatol Ges 2007, 5:1015-1028. 10.1111/j.1610-0387.2007.06538.x, 17976144.
160. Lu H, Goodell V, Disis ML. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008, 7:1388-1394. 10.1021/pr700818f, 18311901.
161. Shoenfeld Y, Zandman-Goddard G, Stojanovich L, Cutolo M, Amital H, Levy Y, Abu-Shakra M, Barzilai O, Berkun Y, Blank M, de Carvalho JF, Doria A, Gilburd B, Katz U, Krause I, Langevitz P, Orbach H, Pordeus V, Ram M, Toubi E, Sherer Y. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases--2008. Isr Med Assoc J 2008, 10:8-12.
162. Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology?. Lupus 2006, 15:737-745. 10.1177/0961203306069344, 17153844.
163. Nolen B, Winans M, Marrangoni A, Lokshin A. Aberrant tumor-associated antigen autoantibody profiles in healthy controls detected by multiplex bead-based immunoassay. J Immunol Methods 2009, 344:116-120. 10.1016/j.jim.2009.03.017, 2706952, 19348809.
164. Voltz R, Carpentier AF, Rosenfeld MR, Posner JB, Dalmau J. P/Q-type voltage-gated calcium channel antibodies in paraneoplastic disorders of the central nervous system. Muscle Nerve 1999, 22:119-122. 10.1002/(SICI)1097-4598(199901)22:1<119::AID-MUS19>3.0.CO;2-5, 9883867.
165. Tschernatsch M, Singh P, Gross O, Gerriets T, Kneifel N, Probst C, Malas S, Kaps M, Blaes F. Anti-SOX1 antibodies in patients with paraneoplastic and non-paraneoplastic neuropathy. J Neuroimmunol 2010, 226:177-180. 10.1016/j.jneuroim.2010.07.005, 20701982.
166. Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltage-gated potassium channel autoimmunity. Neurology 2008, 70:1883-1890. 10.1212/01.wnl.0000312275.04260.a0, 18474843.
167. Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Tureci O, Wiewrodt R, Barnes AC, Robertson JF. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 2008, 63:228-233. 10.1136/thx.2007.083592, 17932110.
168. Farlow EC, Patel K, Basu S, Lee BS, Kim AW, Coon JS, Faber LP, Bonomi P, Liptay MJ, Borgia JA. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res 2010, 16:3452-3462. 10.1158/1078-0432.CCR-09-3192, 20570928.
169. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 1998, 50:652-657.
170. Goodman GE, Thornquist MD, Balmes J, Cullen MR, Meyskens FLJ, Omenn GS, Valanis B, Williams JHJ. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst 2004, 96:1743-1750. 10.1093/jnci/djh320, 15572756.
171. Hocking WG, Hu P, Oken MM, Winslow SD, Kvale PA, Prorok PC, Ragard LR, Commins J, Lynch DA, Andriole GL, Buys SS, Fouad MN, Fuhrman CR, Isaacs C, Yokochi LA, Riley TL, Pinsky PF, Gohagan JK, Berg CD. Lung cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. J Natl Cancer Inst 2010, 102:722-731. 10.1093/jnci/djq126, 20442215.
172. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992, 42:1931-1937.
173. Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001, 124:1138-1148. 10.1093/brain/124.6.1138, 11353730.
174. Altman AJ, Baehner RL. Favorable prognosis for survival in children with coincident opso-myoclonus and neuroblastoma. Cancer 1976, 37:846-852. 10.1002/1097-0142(197602)37:2<846::AID-CNCR2820370233>3.0.CO;2-L, 1253109.
175. Hiyama E, Yokoyama T, Ichikawa T, Hiyama K, Kobayashi M, Tanaka Y, Ueda K, Tanaka Y, Yano H. Poor outcome in patients with advanced stage neuroblastoma and coincident opsomyoclonus syndrome. Cancer 1994, 74:1821-1826. 10.1002/1097-0142(19940915)74:6<1821::AID-CNCR2820740627>3.0.CO;2-A, 8082085.
176. Rojas I, Graus F, Keime-Guibert F, Rene R, Delattre JY, Ramon JM, Dalmau J, Posner JB. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000, 55:713-715.
177. Bei R, Masuelli L, Palumbo C, Modesti M, Modesti A. A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth. Cancer Lett 2009, 281:8-23. 10.1016/j.canlet.2008.11.009, 19091462.
178. Tan EM. Autoimmunity and apoptosis. J Exp Med 1994, 179:1083-1086. 10.1084/jem.179.4.1083, 2191447, 8145031.
179. Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 2008, 222:328-340. 10.1111/j.1600-065X.2008.00611.x, 2719766, 18364012.
180. Ohanian SH, Schlager SI. Humoral immune killing of nucleated cells: mechanisms of complement-mediated attack and target cell defense. Crit Rev Immunol 1981, 1:165-209.
181. Baldwin RW, Robins RA. Induction of tumor-immune responses and their interaction with the developing tumor. Contemp Top Mol Immunol 1977, 6:177-207.
182. Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR, Gambhir SS. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 2010, 51:433-440. 10.2967/jnumed.109.068007, 20150258.
183. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001, 49:146-154. 10.1002/1531-8249(20010201)49:2<146::AID-ANA34>3.0.CO;2-E, 11220734.
184. Monstad SE, Nostbakken JK, Vedeler CA. CRMP5 antibodies found in a patient with limbic encephalitis and myasthenia gravis. J Neurol Neurosurg Psychiatry 2009, 80:241-242. 10.1136/jnnp.2008.149336, 19151024.
185. Monstad SE, Drivsholm L, Skeie GO, Aarseth JH, Vedeler CA. CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Cancer Immunol Immunother 2008, 57:227-232. 10.1007/s00262-007-0369-1, 17657489.
186. Sakai K, Gofuku M, Kitagawa Y, Ogasawara T, Hirose G, Yamazaki M, Koh CS, Yanagisawa N, Steinman L. A hippocampal protein associated with paraneoplastic neurologic syndrome and small cell lung carcinoma. Biochem Biophys Res Commun 1994, 199:1200-1208. 10.1006/bbrc.1994.1358, 7511893.
187. Yang YY, Yin GL, Darnell RB. The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc Natl Acad Sci USA 1998, 95:13254-13259. 10.1073/pnas.95.22.13254, 23773, 9789075.
188. Bataller L, Graus F, Saiz A, Vilchez JJ. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001, 124:437-443. 10.1093/brain/124.2.437, 11157570.
189. Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001, 50:339-348. 10.1002/ana.1288, 11558790.
190. Hoffmann LA, Jarius S, Pellkofer HL, Schueller M, Krumbholz M, Koenig F, Johannis W, la Fougere C, Newman T, Vincent A, Voltz R. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry 2008, 79:767-773. 10.1136/jnnp.2007.118588, 18223018.
191. Carpentier AF, Delattre JY. The Lambert-Eaton myasthenic syndrome. Clin Rev Allergy Immunol 2001, 20:155-158. 10.1385/CRIAI:20:1:155, 11269225.
192. Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, Antoine JC, Rosenblum MK, Rosenfeld MR, Newsom-Davis J, Posner JB, Dalmau J. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 1997, 120:1279-1300. 10.1093/brain/120.8.1279, 9278623.
193. Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002, 59:764-766.
194. Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, Mata S, Kremens D, Vitaliani R, Geschwind MD, Bataller L, Kalb RG, Davis R, Graus F, Lynch DR, Balice-Gordon R, Dalmau J. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009, 65:424-434. 10.1002/ana.21589, 2677127, 19338055.
195. Hermitte L, Martin-Moutot N, Boucraut J, Barone R, Atlan-Gepner C, Seagar M, Pouget J, Kleisbauer JP, Couraud F, Vialettes B. Humoral immunity against glutamic acid decarboxylase and tyrosine phosphatase IA-2 in Lambert-Eaton myasthenic syndrome. J Clin Immunol 2000, 20:287-293. 10.1023/A:1006619820040, 10939716.
196. Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Guzman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010, 9:67-76. 10.1016/S1474-4422(09)70324-2, 2824142, 19962348.
197. Vernino S. Neuronal acetylcholine receptor autoimmunity. Ann N Y Acad Sci 2008, 1132:124-128. 10.1196/annals.1405.011, 18567861.
198. Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000, 47:297-305. 10.1002/1531-8249(200003)47:3<297::AID-ANA4>3.0.CO;2-4, 10716248.
199. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol 2001, 50:301-311. 10.1002/ana.1127, 11558786.
200. Sabater L, Gomez-Choco M, Saiz A, Graus F. BR serine/threonine kinase 2: a new autoantigen in paraneoplastic limbic encephalitis. J Neuroimmunol 2005, 170:186-190. 10.1016/j.jneuroim.2005.08.011, 16165222.
201. Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. BMC Ophthalmol 2004, 4:5. 10.1186/1471-2415-4-5, 446200, 15180904.
202. Adamus G, Aptsiauri N, Guy J, Heckenlively J, Flannery J, Hargrave PA. The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Clin Immunol Immunopathol 1996, 78:120-129. 10.1006/clin.1996.0021, 8625554.
203. Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L, Casamitjana R, Ramio-Torrenta L, Graus F. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008, 131:2553-2563. 10.1093/brain/awn183, 18687732.
204. Bazhin AV, Shifrina ON, Savchenko MS, Tikhomirova NK, Goncharskaia MA, Gorbunova VA, Senin II, Chuchalin AG, Philippov PP. Low titre autoantibodies against recoverin in sera of patients with small cell lung cancer but without a loss of vision. Lung Cancer 2001, 34:99-104. 10.1016/S0169-5002(01)00212-4, 11557119.
205. Maddison P, Thorpe A, Silcocks P, Robertson JF, Chapman CJ. Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Lung Cancer 2010, 70:335-339. 10.1016/j.lungcan.2010.03.002, 20371131.
206. Takamori M, Takahashi M, Yasukawa Y, Iwasa K, Nemoto Y, Suenaga A, Nagataki S, Nakamura T. Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. J Neurol Sci 1995, 133:95-101. 10.1016/0022-510X(95)00162-U, 8583238.
207. Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004, 62:778-782. 2574539, 15007130.
208. Sabater L, Bataller L, Suarez-Calvet M, Saiz A, Dalmau J, Graus F. ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. J Neuroimmunol 2008, 201-202:163-165. 10.1016/j.jneuroim.2008.01.018, 2582201, 18639938.